On the other hand, in AML with aberrations rendering their LSCs positively responsive to atRA, there might even be a therapeutic role for RAR antagonists, even though the effects of atRA on normal HSCs [49,50,51,52] need to be carefully considered in this context. Here, RARA is linked to acute myeloid leukemia.